Haisco
Haisco Pharmaceutical Group is a Chinese healthcare company focused on the research and development of therapeutic drugs.
Launch date
Employees
Market cap
€4.6b
Enterprise valuation
€4.7b (Public information from Sep 2024)
Share price
CNY33.02 002653.SZ
Tibet China (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 3.3b | 2.8b | 3.0b | 3.4b | 4.0b | 5.0b | 6.2b |
| % growth | (15 %) | (17 %) | 9 % | 11 % | 19 % | 25 % | 24 % |
| EBITDA | 841m | 694m | 607m | 576m | 602m | 927m | 1.3b |
| % EBITDA margin | 25 % | 25 % | 20 % | 17 % | 15 % | 19 % | 21 % |
| Profit | 637m | 345m | 277m | 295m | 402m | 594m | 948m |
| % profit margin | 19 % | 12 % | 9 % | 9 % | 10 % | 12 % | 15 % |
| EV / revenue | 5.6x | 7.8x | 7.9x | 7.6x | 8.6x | 6.9x | 5.5x |
| EV / EBITDA | 22.1x | 31.3x | 39.1x | 44.4x | 57.2x | 37.1x | 27.0x |
| R&D budget | 406m | 434m | 448m | 517m | - | - | - |
| R&D % of revenue | 12 % | 16 % | 15 % | 15 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
Recent News about Haisco
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
ACQUISITION by Asensus Surgical Sep 2018
